Description:

ADVL0212: Reporting Period Worksheet (Leukemia) FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C0F387DC-C9D3-5664-E034-0003BA12F5E7

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C0F387DC-C9D3-5664-E034-0003BA12F5E7

Keywords:
Versions (5) ▾
  1. 8/26/12
  2. 1/8/15
  3. 1/9/15
  4. 1/9/15
  5. 3/12/15
Uploaded on:

March 12, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Brain and Central Nervous System Tumors NCT00053963 Treatment - ADVL0212: Reporting Period Worksheet (Leukemia) - 2172521v3.0

No Instruction available.

  1. StudyEvent: ADVL0212: Reporting Period Worksheet (Leukemia)
    1. No Instruction available.
Header
Patient characteristics
cm
Kg
Was patient's bone marrow status evaluated during this reporting interval?
does patient have bone marrow involvement?
Was patients shortening fraction determined by echocardiogram?
%
Is patient off protocol therapy at the end of this reporting period?
reason treatment ended
Did resting heart rate increase by 35%?
check all that apply
check all that apply
Was there a T wave inversion in leads II, III, AVF (inferior leads) or V4, V5, and V6 (lateral leads)?
Was ST segment at the J-point greater than or equal to 2 mm below baseline in leads II, II AVF (inferior leads), V4, V5, V6 (lateral leads)?
Was there a change to LVEF?
%
Treatment
Were any of the infusions of Depsipeptide interrupted for any reason?
Was there a deviation from protocol therapy?
Did the patient receive radiation therapy during this reporting period?
Was tumor tissue surgically obtained for biology studies (e.g. biopsy, resection, fine needle aspiration)?
Concomitant Medication
Did patient receive concomitant medications while on protocol therapy?
Type
New Cancer
Has a new primary cancer of MDS been diagnosed that has not been previously reported?
Follow-Up
Vital Status
Was the patient unable to be contacted for current scheduled follow-up?
Was patient enrolled on another COG therapeutic study at the end of this reporting period?
Was patient's consent withdrawn?
Did patient relapse or experience disease progression during this reporting period?
Adverse event
Category
Type
Code
Attribution
Adverse Drug Experience?
Dose Limiting Toxicity?
check box if not resolved [toxicity]